CNBC

Merck's pneumococcal shot shows promise in children and teens in study

Merck's pneumococcal vaccine showed strong immune responses in children and teens who are at higher risk of serious illness in a late-stage study, the drugmaker said on Thursday. The shot, Capvaxive, ...
Medscape

Pneumococcal Conjugate Vaccine V116 Extends Protection to Adults Living With HIV

In adults living with HIV, the 21-valent pneumococcal conjugate vaccine (PCV) V116 was well tolerated and effective against all 21 target serotypes. The immune responses were comparable to those ...
WebMD

Capvaxive: 21-Valent Pneumococcal Conjugate Vaccine Adds Broader Strain Coverage and a New FDA Indication for High-Risk Children and Teens

What Is It, and Why Does It Matter? Capvaxive is a 21-valent pneumococcal conjugate vaccine (PCV21). It trains your immune system to recognize 21 types of Streptococcus pneumoniae, a germ that can ...
The Conversation

There’s a new vaccine for pneumococcal disease in Australia. Here’s what to know

The Australian government announced last week there’s a new vaccine for pneumococcal disease on the National Immunisation Program for all children. This vaccine replaces previously listed pneumococcal ...
Reuters

Merck's pneumococcal shot shows promise in at-risk children and teens

Sept 11 (Reuters) - Merck's (MRK.N), opens new tab pneumococcal vaccine triggered immune responses in children and teens who are at higher risk of serious illness in a late-stage study, the drugmaker ...